IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.592
NA - Nord America 582
EU - Europa 301
SA - Sud America 18
OC - Oceania 11
AF - Africa 7
Totale 4.511
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.860
US - Stati Uniti d'America 549
CN - Cina 391
HK - Hong Kong 290
GB - Regno Unito 88
DE - Germania 65
CZ - Repubblica Ceca 34
IT - Italia 34
CA - Canada 19
IN - India 18
FI - Finlandia 16
NL - Olanda 15
BR - Brasile 14
AU - Australia 11
MX - Messico 11
JP - Giappone 9
FR - Francia 8
PL - Polonia 8
ZA - Sudafrica 7
BE - Belgio 6
UA - Ucraina 6
TR - Turchia 5
TW - Taiwan 4
ID - Indonesia 3
LT - Lituania 3
PT - Portogallo 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AT - Austria 2
CL - Cile 2
EE - Estonia 2
GE - Georgia 2
IE - Irlanda 2
PK - Pakistan 2
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
ES - Italia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
YE - Yemen 1
Totale 4.511
Salva come PNG Salva come JPEG
Città #
Hong Kong 288
Singapore 189
Hefei 161
Ashburn 124
Boardman 93
London 72
Beijing 71
Shanghai 51
Munich 38
Los Angeles 29
Council Bluffs 24
Brno 23
Rome 23
San Francisco 23
Dallas 21
Redmond 21
Amsterdam 14
Pune 13
Guangzhou 11
Santa Clara 11
Seattle 11
Mexico City 10
Olomouc 10
Turku 10
New York 9
São Paulo 9
Toronto 9
Boston 8
Tokyo 8
Washington 8
Brooklyn 7
Manchester 7
Helsinki 6
Warsaw 6
Chicago 5
Melbourne 5
Shenzhen 4
Atlanta 3
Canberra 3
Haikou 3
Hangzhou 3
Johannesburg 3
Mol 3
Montreal 3
Paris 3
Stockholm 3
Sydney 3
Taipei 3
The Dalles 3
Wuhan 3
Ankara 2
Augusta 2
Aversa 2
Chennai 2
Concord 2
Dublin 2
Genoa 2
Hanover 2
Hasselt 2
Iowa City 2
Lodz 2
Luoyang 2
New Delhi 2
North Liberty 2
Oklahoma City 2
Phoenix 2
Porto 2
Tallinn 2
Tbilisi 2
Tirana 2
Topeka 2
Vilnius 2
West Jordan 2
Xiamen 2
Zhengzhou 2
Almaty 1
Berlin 1
Birmingham 1
Bismarck 1
Brussels 1
Cartagena 1
Central District 1
Centurion 1
Changchun 1
Changsha 1
Charlotte 1
Chongqing 1
Clarksburg 1
Clifton 1
Colombo 1
Columbia 1
Dalian 1
David 1
Dhaka 1
Frankfurt am Main 1
Fuyang 1
Fuzhou 1
Grand Rapids 1
Guiyang 1
Handan 1
Totale 1.546
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 195
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 182
Cancer drugs and QT prolongation: weighing risk against benefit 182
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 182
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 173
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 171
Minimal sampling colistin pharmacokinetics in critically ill patients 170
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 168
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 168
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 161
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 155
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 152
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 135
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 115
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 104
Anthracyclines 103
Anthracycline Cardiotoxicity 100
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 94
Anthracycline Cardiotoxicity 87
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 83
Cardiotoxicity of antitumor drugs 72
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 67
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 66
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 60
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 44
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 44
What is cardiotoxicity? 42
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 36
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 36
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 36
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 35
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 34
Isavuconazole: case report and pharmacokinetic considerations 33
Pharmacology of Cardio-Oncology 33
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 32
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 32
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 32
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 31
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 31
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 30
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 29
The concomitant management of cancer therapy and cardiac therapy 29
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 29
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 27
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 27
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 27
Pharmacological Foundation of Cardio-Oncology 25
Matters of the heart: The case of TNF-alpha targeting drugs 25
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 25
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 25
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 25
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 24
Doxorubicin degradation in cardiomyocytes 23
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 23
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 22
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 22
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 22
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 21
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 21
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 21
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 21
Translating molecular mechanisms into clinical facts 21
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 21
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 21
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 20
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 20
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 20
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 20
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 20
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 19
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 19
Molecular determinants of the reduced cardiotoxicity of epirubicin 19
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 19
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 19
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 18
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 18
Do you know pixantrone? 17
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 17
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 16
The reality of pixantrone in real life 15
Humans and Rodents: The Case of hOAT4 and mOat5 12
Totale 4.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.148
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 4 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/20253.593 74 34 107 13 42 68 37 20 222 238 1.303 1.435
2025/2026485 294 186 5 0 0 0 0 0 0 0 0 0
Totale 4.590